

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

- 1-32. (Canceled)
33. (Previously presented) A method of degrading a prostate tumor in a mammal comprising local administration to the prostate of a composition comprising therapeutically effective concentrations of collagenase, hyaluronidase, and calcium ions.
34. (Previously presented) The method of claim 33, wherein the composition comprises about 1 mM to about 50 mM calcium ions.
35. (Previously presented) The method of claim 33, wherein the calcium ions comprise a calcium salt.
36. (Previously presented) The method of claim 35, wherein the calcium salt comprises calcium chloride.
37. (Canceled)
38. (Previously presented) The method of claim 33, wherein the composition comprises about 1 mM to about 50 mM calcium ions, about 250 to about 250,000 U/ml collagenase and about 160 to about 160,000 U/ml hyaluronidase.
39. (Canceled)
40. (Previously presented) The method of claim 33, wherein the composition further comprises an effective concentration of a nonionic surfactant.

41. (Currently amended) The method of claim 40, wherein the nonionic surfactant comprises octylphenoxy polyethoxyethanol an alkylphenylpolyoxethylene surfactant.
42. (Previously presented) The method of claim 33, wherein the composition further comprises an effective concentration of an antibiotic.
43. (Previously presented) The method of claim 42, wherein the antibiotic comprises gentamicin sulfate.
44. (Previously presented) The method of claim 33, wherein local administration comprises intraprostatic injection.
45. (Previously presented) The method of claim 44, wherein intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.
46. (Previously presented) The method of claim 44, comprising administering a single injection of about 1 to 50 ml.
47. (Previously presented) The method of claim 44, comprising administering a single injection of about 1 to 5 ml.
48. (Previously presented) The method of claim 33, wherein local administration comprises administering a depot formulation.
49. (Previously presented) The method of claim 33, wherein local administration comprises administering a slow release implant, a microencapsulated composition, a conjugate with a biodegradable polymer, or a conjugate with a prostate-specific immunoglobulin.
50. (Previously presented) A method of degrading a prostate tumor in a mammal comprising local administration to the prostate of a sterile pyrogen-free solution comprising effective

concentrations of calcium ions, collagenase, hyaluronidase, a nonionic surfactant, an antibiotic, and a pharmaceutically acceptable aqueous carrier having a physiologic pH; wherein the solution is suitable for administration to living mammals at single or multiple dosages of about 1 to 50 ml via intraprostatic injection; and wherein administration of said solution causes the necrosis, liquification, and regression of said tumor.

51. (Previously presented) The method of claim 50, wherein collagenase is provided at a concentration of about 2,500 to 25,000 U/ml.
52. (Previously presented) The method of claim 50, wherein hyaluronidase is provided at a concentration of about 1,600 to 16,000 U/ml.
53. (Canceled)
54. (Currently amended) The method of claim 50, wherein the nonionic surfactant comprises octylphenoxypolyethoxyethanol ~~an alkylphenylpolyoxethylene surfactant~~.
55. (Previously presented) The method of claim 50, wherein the antibiotic comprises gentamicin.
56. (Previously presented) The method of claim 50, wherein the intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.
57. (Previously presented) The method of claim 50, comprising administering a single injection of about 1 to 20 ml.
58. (Canceled)